Follow
Valesca Retel
Valesca Retel
Unknown affiliation
Verified email at nki.nl
Title
Cited by
Cited by
Year
Use of 70-gene signature to predict prognosis of patients with node-negative breast cancer: a prospective community-based feasibility study (RASTER)
JM Bueno-de-Mesquita, WH van Harten, VP Retel, LJ van't Veer, ...
The lancet oncology 8 (12), 1079-1087, 2007
3332007
A prospective evaluation of a breast cancer prognosis signature in the observational RASTER study
CA Drukker, JM Bueno‐de‐Mesquita, VP Retèl, WH van Harten, ...
International journal of cancer 133 (4), 929-936, 2013
2832013
Tumor-infiltrating lymphocyte therapy or ipilimumab in advanced melanoma
MW Rohaan, TH Borch, JH Van Den Berg, Ö Met, R Kessels, ...
New England journal of medicine 387 (23), 2113-2125, 2022
1392022
Impact of organ-on-a-chip technology on pharmaceutical R&D costs
N Franzen, WH van Harten, VP Retèl, P Loskill, ...
Drug discovery today 24 (9), 1720-1724, 2019
1312019
Impact of mammographic screening on the detection of good and poor prognosis breast cancers
LJ Esserman, Y Shieh, EJT Rutgers, M Knauer, VP Retèl, S Mook, ...
Breast cancer research and treatment 130, 725-734, 2011
1242011
Cost-effectiveness of the 70-gene signature versus St. Gallen guidelines and Adjuvant Online for early breast cancer
VP Retèl, MA Joore, M Knauer, SC Linn, M Hauptmann, WH van Harten
European journal of cancer 46 (8), 1382-1391, 2010
1152010
Metastatic potential of T1 breast cancer can be predicted by the 70-gene MammaPrint signature
S Mook, M Knauer, JM Bueno-de-Mesquita, VP Retel, J Wesseling, ...
Annals of surgical oncology 17, 1406-1413, 2010
1012010
Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy versus palliative systemic chemotherapy in stomach cancer patients with peritoneal dissemination, the study …
WJ Koemans, RT van der Kaaij, H Boot, T Buffart, AAFA Veenhof, ...
BMC cancer 19, 1-8, 2019
852019
A systematic and critical review of the evolving methods and applications of value of information in academia and practice
L Steuten, G van de Wetering, K Groothuis-Oudshoorn, V Retèl
Pharmacoeconomics 31, 25-48, 2013
832013
A cost-effectiveness analysis of a preventive exercise program for patients with advanced head and neck cancer treated with concomitant chemo-radiotherapy
VP Retèl, L van der Molen, FJM Hilgers, CRN Rasch, AA l'Ortye, ...
BMC cancer 11, 1-9, 2011
572011
Cost effectiveness of interval cytoreductive surgery with hyperthermic intraperitoneal chemotherapy in stage III ovarian cancer on the basis of a randomized phase III trial
SN Koole, C Van Lieshout, WJ Van Driel, E Van Schagen, K Sikorska, ...
Obstetrical & Gynecological Survey 74 (10), 592-593, 2019
482019
Integration of a smoking cessation program in the treatment protocol for patients with head and neck and lung cancer
JC de Bruin-Visser, AH Ackerstaff, H Rehorst, VP Retèl, FJM Hilgers
European Archives of Oto-Rhino-Laryngology 269, 659-665, 2012
472012
Scenario drafting to anticipate future developments in technology assessment
VP Retèl, MA Joore, SC Linn, EJT Rutgers, WH van Harten
BMC research notes 5, 1-12, 2012
442012
Knowledge of genomic testing among early‐stage breast cancer patients
AR Richman, JP Tzeng, LA Carey, VP Retèl, NT Brewer
Psycho‐Oncology 20 (1), 28-35, 2011
422011
Determinants and effects of positive surgical margins after prostatectomy on prostate cancer mortality: a population-based study
VP Retèl, C Bouchardy, M Usel, I Neyroud-Caspar, F Schmidlin, G Wirth, ...
BMC urology 14, 1-11, 2014
412014
The multigene signature MammaPrint impacts on multidisciplinary team decisions in ER+, HER2 early breast cancer
R Exner, Z Bago-Horvath, R Bartsch, M Mittlboeck, VP Retel, F Fitzal, ...
British journal of cancer 111 (5), 837-842, 2014
412014
Constructive Technology Assessment (CTA) as a tool in coverage with evidence development: the case of the 70-gene prognosis signature for breast cancer diagnostics
VP Retèl, JM Bueno-de-Mesquita, MJM Hummel, MJ van de Vijver, ...
International journal of technology assessment in health care 25 (1), 73-83, 2009
402009
Review on early technology assessments of nanotechnologies in oncology
VP Retèl, MJM Hummel, WH van Harten
Molecular oncology 3 (5-6), 394-401, 2009
392009
Prospective cost-effectiveness analysis of genomic profiling in breast cancer
VP Retel, MA Joore, CA Drukker, JM Bueno-de-Mesquita, M Knauer, ...
European journal of cancer 49 (18), 3773-3779, 2013
362013
Understanding the costs of surgery: a bottom-up cost analysis of both a hybrid operating room and conventional operating room
S Patel, M Lindenberg, MM Rovers, WH Van Harten, TJM Ruers, L Poot, ...
International journal of health policy and management 11 (3), 299, 2022
312022
The system can't perform the operation now. Try again later.
Articles 1–20